Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA

6/14/24 4:11:53 AM ET

$EDIT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $EDIT alert in real time by email

All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusion
Patients had early normalization of total hemoglobin with a mean within the normal range at >14 g/dL and rapid and sustained improvements in fetal hemoglobin well above levels of >40%.
Reni-cel was well-tolerated and demonstrated a safety profile consistent with myeloablative conditioning with busulfan and autologous hematopoietic stem cell transplant

Get the next $EDIT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EDIT

Date	Price Target	Rating	Analyst
11/6/2024		In-line → Outperform	Evercore ISI
11/4/2024		Outperform → Mkt Perform	Raymond James
8/8/2024	$13.00 → $15.00	Neutral → Buy	BofA Securities
5/9/2024	$7.00	Underweight → Equal-Weight	Morgan Stanley
10/24/2023	$11.00	Neutral → Buy	Citigroup
10/18/2023	$8.00	Underweight → Neutral	JP Morgan
10/17/2023		Overweight → Neutral	Cantor Fitzgerald
9/29/2023	$9.00 → $17.00	Hold → Buy	Stifel

More analyst ratings

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company's first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine's commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company's current and future pipeline of products. "As we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren's caliber to Editas. Caren has a proven ability to translate early discovery and clinical assets into
9/25/23 9:00:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen
8/28/23 7:00:57 AM ET
$EDIT
$MDNA
$TNGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage genome editing company, today announced the appointment of Linda C. Burkly, Ph.D., as the Company's Executive Vice President and Chief Scientific Officer. Dr. Burkly will lead Editas' drug discovery team and activities related to Editas Medicine's pipeline of experimental medicines across all therapeutic areas and indications. "Earlier this year, we shared our vision to be a leader in programable in vivo gene editing, and I couldn't be happier that Linda is joining Editas to help make this vision a reality. Linda has an outstanding track record of inventing or contributing to the fo
7/24/23 7:00:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$EDIT
Financials

Live finance-specific insights

Editas Medicine Announces Third Quarter 2024 Results and Business Updates
Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on its in vivo progress and pipeline development in 1Q 2025 Company expects the existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI
11/4/24 7:30:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine's proprietary targeted LNP as a key step forward toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Initiated process to partner or out-license reni-cel to focus resources on in vivo pipeline development Company to present data and discuss strategic update in a Company-sponsored Webinar today at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced its achievement of in vivo preclinical proof of concept of hematopoietic
10/22/24 7:00:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
On track to present additional clinical data from the RUBY trial and the EdiTHAL trial by year-end In vivo preclinical proof-of-concept for an undisclosed indication on-track by year-end Strong financial position with runway into 2026 CAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today reported financial results for the second quarter 2024 and provided business updates. "We made significant progress in all three pillars of our strategy this quarter, particularly reni-cel as we shared a substantial clinical update mid-year and continued to enroll and dose at an accelerated pace. With these data, we are hig
8/7/24 7:00:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

$EDIT
Press Releases

Fastest customizable press release news feed in the world

Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced that management will participate in the following upcoming investor conferences in November and December: Guggenheim's Inaugural Healthcare Innovation ConferenceFormat: Fireside ChatDate: Tuesday, November 12Time: 4:00 p.m. ETLocation: Boston, MA Stifel 2024 Healthcare ConferenceFormat: Fireside ChatDate: Tuesday, November 19Time: 1:50 p.m. ETLocation: New York, NY 7th Annual Evercore ISI HealthCONx ConferenceFormat: Fireside ChatDate: Tuesday, December 3Time: 1:20 p.m. ETLocation: Coral Gables, FL To access the live webcasts of Editas Medicine
11/6/24 9:00:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Editas Medicine Announces Third Quarter 2024 Results and Business Updates
Achieved in vivo preclinical proof of concept of HBG1/2 editing in hematopoietic stem and progenitor cells (HSPCs) using Editas Medicine's proprietary targeted LNP in a key step to developing a novel in vivo treatment for sickle cell disease and beta thalassemia On track to share additional clinical and patient reported outcomes data from 28 patients in the RUBY trial for sickle cell disease at the American Society of Hematology (ASH) Annual Meeting and Exposition in December Company to provide an update on its in vivo progress and pipeline development in 1Q 2025 Company expects the existing cash, cash equivalents, and marketable securities, together with the upfront cash payment from DRI
11/4/24 7:30:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas Medicine's proprietary targeted LNP as a key step forward toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia Initiated process to partner or out-license reni-cel to focus resources on in vivo pipeline development Company to present data and discuss strategic update in a Company-sponsored Webinar today at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a clinical-stage gene editing company, today announced its achievement of in vivo preclinical proof of concept of hematopoietic
10/22/24 7:00:00 AM ET
$EDIT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care

Editas Medicine Reveals Updated Safety And Efficacy Results From The RUBY Trial Of Reni-Cel In 18 Sickle Cell Patients At EHA

Chat with this insight

Recent Analyst Ratings for $EDIT

$EDIT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

EVP, CHIEF MEDICAL OFFICER Mei Baisong sold $1,774 worth of shares (518 units at $3.42), decreasing direct ownership by 0.39% to 133,895 units (SEC Form 4)

CEO O'Neill Gilmore Neil sold $5,325 worth of shares (1,555 units at $3.42), decreasing direct ownership by 0.49% to 313,724 units (SEC Form 4)

EVP, CHIEF SCIENTIFIC OFFICER Burkly Linda sold $64,370 worth of shares (11,886 units at $5.42), decreasing direct ownership by 14% to 73,136 units (SEC Form 4)

$EDIT Market Insights

Live Market Insights

Unveiling 5 Analyst Insights On Editas Medicine

Oppenheimer Maintains Perform on Editas Medicine, Maintains $12 Price Target

Editas Medicine Unveils Updated Safety And Efficacy Results From The EdiTHAL Trial Of Reni-cel In 7 Patients With Transfusion-Dependent Beta Thalassemia At EHA

$EDIT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Editas Medicine upgraded by Evercore ISI

Editas Medicine downgraded by Raymond James

Editas Medicine upgraded by BofA Securities with a new price target

$EDIT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

Amendment: SEC Form SC 13G/A filed by Editas Medicine Inc.

$EDIT Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Hopfield Jessica bought $253,868 worth of shares (45,000 units at $5.64), increasing direct ownership by 198% to 67,700 units (SEC Form 4)

$EDIT Leadership Updates

Live Leadership Updates

$EDIT SEC Filings

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer

SEC Form 10-Q filed by Editas Medicine Inc.

Editas Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Editas Medicine Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

$EDIT Financials

Live finance-specific insights

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

Editas Medicine Announces Second Quarter 2024 Results and Business Updates

$EDIT Press Releases

Fastest customizable press release news feed in the world

Editas Medicine to Participate in Upcoming Investor Conferences

Editas Medicine Announces Third Quarter 2024 Results and Business Updates

Editas Medicine Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update

Recent Analyst Ratings for
$EDIT

$EDIT
Insider Trading

$EDIT
Market Insights

$EDIT
Analyst Ratings

$EDIT
Large Ownership Changes

$EDIT
Insider Purchases

$EDIT
Leadership Updates

$EDIT
SEC Filings

$EDIT
Financials

$EDIT
Press Releases